Patents Assigned to MolMed SpA
-
Patent number: 10314925Abstract: A polynucleotide comprising a nucleotide sequence encoding a thymidine kinase wherein at least one of the nucleotides corresponding to the splice donor site nucleotides is replaced by another nucleotide and wherein the nucleotides of the splice acceptor sites are not altered.Type: GrantFiled: November 15, 2018Date of Patent: June 11, 2019Assignee: MolMed SpAInventors: Francesca Salvatori, Stefania Massa, Marina Radrizzani, Salvatore Toma
-
Patent number: 10155052Abstract: A polynucleotide comprising a nucleotide sequence encoding a thymidine kinase wherein at least one of the nucleotides corresponding to the splice donor site nucleotides is replaced by another nucleotide and wherein the nucleotides of the splice acceptor sites are not altered.Type: GrantFiled: April 1, 2015Date of Patent: December 18, 2018Assignee: MolMed SpAInventors: Francesca Salvatori, Stefania Massa, Marina Radrizzani, Salvatore Toma
-
Patent number: 9782496Abstract: A pharmaceutical composition comprising a conjugate of a cytokine and a tumor targeting moiety (TTM) and a pharmaceutically acceptable excipient, wherein the cytokine is present in an amount which does not induce a negative feedback mechanism.Type: GrantFiled: July 29, 2015Date of Patent: October 10, 2017Assignee: MolMed SpAInventors: Angelo Corti, Flavio Curnis
-
Patent number: 9119886Abstract: A pharmaceutical composition comprising a conjugate of a cytokine and a tumor targeting moiety (TTM) and a pharmaceutically acceptable excipient, wherein the cytokine is present in an amount which does not induce a negative feedback mechanism.Type: GrantFiled: April 30, 2010Date of Patent: September 1, 2015Assignee: MolMed SpAInventors: Angelo Corti, Flavio Curnis
-
Patent number: 9005945Abstract: A polynucleotide comprising a nucleotide sequence encoding a thymidine kinase wherein at least one of the nucleotides corresponding to the splice donor site nucleotides is replaced by another nucleotide and wherein the nucleotides of the splice acceptor sites are not altered.Type: GrantFiled: December 10, 2013Date of Patent: April 14, 2015Assignee: MolMed SpAInventors: Francesca Salvatori, Stefania Massa, Marina Radrizzani, Salvatore Toma
-
Patent number: 8912152Abstract: A polynucleotide comprising a nucleotide sequence encoding Vif, wherein each of the amino acids corresponding to positions 127, 128, 130, 131, 132 and 142 of the amino acid sequence in FIG. 1A representing the Vif wild-type consensus sequence, are replaced with another amino acid, and wherein the nucleotide sequence does not encode the amino acid sequence shown in FIG. 2, representing the Vif sequence of the F12 non-producer variant of HIV-1.Type: GrantFiled: March 7, 2006Date of Patent: December 16, 2014Assignee: MolMed SpaInventor: Chiara Bovolenta
-
Publication number: 20140178345Abstract: A polynucleotide comprising a nucleotide sequence encoding a thymidine kinase wherein at least one of the nucleotides corresponding to the splice donor site nucleotides is replaced by another nucleotide and wherein the nucleotides of the splice acceptor sites are not altered.Type: ApplicationFiled: December 10, 2013Publication date: June 26, 2014Applicant: MolMed SpAInventors: Francesca SALVATORI, Stefania MASSA, Marina RADRIZZANI, Salvatore TOMA
-
Patent number: 8642311Abstract: A polynucleotide comprising a nucleotide sequence encoding a thymidine kinase wherein at least one of the nucleotides corresponding to the splice donor site nucleotides is replaced by another nucleotide and wherein the nucleotides of the splice acceptor sites are not altered.Type: GrantFiled: August 31, 2012Date of Patent: February 4, 2014Assignee: MolMed SpAInventors: Marina Radrizzani, Salvatore Toma, Francesca Salvatori, Stefania Massa
-
Patent number: 8357788Abstract: A polynucleotide comprising a nucleotide sequence encoding a thymidine kinase wherein at least one of the nucleotides corresponding to the splice donor site nucleotides is replaced by another nucleotide and wherein the nucleotides of the splice acceptor sites are not altered.Type: GrantFiled: June 17, 2005Date of Patent: January 22, 2013Assignee: MolMed SpAInventors: Marina Radrizzani, Salvatore Toma, Francesca Salvatori, Stefania Massa
-
Publication number: 20100310506Abstract: A pharmaceutical composition comprising a conjugate of a cytokine and a tumor targeting moiety (TTM) and a pharmaceutically acceptable excipient, wherein the cytokine is present in an amount which does not induce a negative feedback mechanism.Type: ApplicationFiled: April 30, 2010Publication date: December 9, 2010Applicant: MolMed SpaInventors: Angelo Corti, Flavio Curnis
-
Patent number: 7795386Abstract: Disclosed herein are peptides which include an isoDGR motif and which selectively inhibit ?v?3 integrin. In some embodiments, the isoDGR motif results from the deamidation of an NGR motif.Type: GrantFiled: December 21, 2005Date of Patent: September 14, 2010Assignees: Molmed SpA, Fondazione Centro San Raffaele del Monte TaborInventors: Angelo Corti, Flavio Curnis
-
Publication number: 20090130069Abstract: A polynucleotide comprising a nucleotide sequence encoding a thymidine kinase wherein at least one of the nucleotides corresponding to the splice donor site nucleotides is replaced by another nucleotide and wherein the nucleotides of the splice acceptor sites are not altered.Type: ApplicationFiled: June 17, 2005Publication date: May 21, 2009Applicant: MolMed SpAInventors: Marina Radrizzani, Salvatore Toma, Francesca Salvatori, Stefania Massa
-
Publication number: 20080286248Abstract: A polynucleotide comprising a nucleotide sequence encoding Vif, wherein each of the amino acids corresponding to positions 127, 128, 130, 131, 132 and 142 of the amino acid sequence in FIG. 1A representing the Vif wild-type consensus sequence, are replaced with another amino acid, and wherein the nucleotide sequence does not encode the amino acid sequence shown in FIG. 2, representing the Vif sequence of the F12 non-producer variant of HIV-1.Type: ApplicationFiled: March 7, 2006Publication date: November 20, 2008Applicant: MolMed SpaInventor: Chiara Bovolenta
-
Publication number: 20080286305Abstract: A delivery system comprising a T cell comprising at least one antigen capable of loading antigen-presenting-cells with the antigen.Type: ApplicationFiled: June 13, 2008Publication date: November 20, 2008Applicant: MolMed SpaInventors: Catia Traversari, Claudio Bordignon
-
Patent number: 7413733Abstract: A delivery system comprising a T cell comprising at least one antigen capable of loading antigen-presenting-cells with the antigen.Type: GrantFiled: October 21, 2003Date of Patent: August 19, 2008Assignee: MolMed SpAInventors: Catia Traversari, Claudio Bordignon
-
Publication number: 20070166291Abstract: A method for transduction of cells with a genetic construct and selection of genetically modified cells, the method comprising performing the transduction and selection in a closed system.Type: ApplicationFiled: May 5, 2005Publication date: July 19, 2007Applicant: MOLMED SPAInventors: Claudia Benati, Robert Sciarretta, Simona La Seta Catamancio, Marina Radrizzani, Cecilia Sendresen, Salvatore Toma
-
Publication number: 20040087537Abstract: A conjugate comprising a first and second sequence, wherein the first sequence comprises at least part of the human low affinity Nerve Growth Factor receptor (LNGFR) or a polynucleotide coding for LNGFR, and the second sequence comprises at least part of a mutant HIV Nef or a polynucleotide coding for F12Nef.Type: ApplicationFiled: August 29, 2003Publication date: May 6, 2004Applicant: MOLMED SPAInventor: Maurizio Federico
